68 results about "Anti coagulation" patented technology

This invention discloses a blood purification device and medical system. The blood purification device includes: a device housing; a blood purifier; a blood tubing assembly, the blood tubing assembly including a first blood tubing connecting a human blood vessel to the inlet of the blood purifier and a second blood tubing connecting the outlet of the blood purifier to the human blood vessel; a power assembly including a blood pump for driving blood flow within the blood tubing assembly, a first replenishment pump for allowing anticoagulant solution to flow into the first blood tubing, and / or a second replenishment pump for allowing calcium solution to flow into the second blood tubing; and a blood component analysis component disposed within the device housing, the blood component analysis component being used to detect collected blood samples. This design facilitates the appropriate adjustment of anticoagulant drugs and calcium ions in the blood purification circuit.

The invention relates to the technical field of detection kits, in particular to a blood coagulation reaction linked lupus anticoagulant fluorescence detection kit and application thereof, the kit contains a screening-confirmation integrated reagent, a calibration product, a quality control product and an anticoagulation interference inhibitor; the integrated reagent is divided into a reagent A and a reagent B, the reagent A contains a buffer solution, recombinant snake venom thrombin, composite phospholipid, a fluorescent substrate and other components, and the reagent B contains prothrombin, calcium ions, high-concentration composite phospholipid and other components; the composite phospholipid system is formed according to a specific proportion and modifies beta2-glycoprotein I, the fluorescence enhancement-stabilization system is formed by matching a Schiff base compound with a stabilizer, the calibrator is a series of lupus anticoagulant standard substances, and the quality control substance comprises simulants with different concentrations and negative control. The anti-interference capability is high, and the influence of anti-coagulant drugs and enzyme source fluctuation is reduced; the signal amplification effect is obvious, the detection sensitivity is high and the reagent stability is good; the operation is simple and convenient, screening and confirmation are integrally completed, and a conventional fluorescence detector is adapted.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The invention discloses a valve preparation method. The method comprises the following steps: performing decellularization treatment on a bovine pericardium material to be treated; enhancing the porosity of the decellularized bovine pericardium material through a physical and / or chemical method so as to promote the regeneration of native valve leaflet cells and tissues, and obtaining a composite material; and cutting the leaflet of the composite material to obtain the valve. The bovine pericardial valve which is high in durability, free of anticoagulation, excellent in biocompatibility, excellent in calcification resistance and low in immunogenicity can be prepared, and therefore the purpose of treating heart valve diseases is achieved.

The invention provides an anti-coagulation coating. The anti-coagulation coating comprises an anti-coagulation component and a cross-linking agent, the preparation method of the anti-coagulation coating comprises the following steps: plasma activation: carrying out surface activation treatment on the surface of the conduit by adopting plasma; preparing a surface anti-coagulation coating: firstly preparing an anti-coagulation solution, immersing the catheter in the anti-coagulation solution containing phosphorylcholine, placing the catheter at room temperature after dip-coating, then placing the catheter in a curing box for curing, and taking out the catheter after the catheter is cooled to the room temperature, so as to prepare the catheter with the anti-coagulation coating containing phosphorylcholine; according to the anticoagulant coating, complications such as thrombus and fibrin sheath are reduced, the safety of a product is improved, anaphylactic reaction caused by drugs and heparin is avoided, and a passive anticoagulation mode is adopted, so that the blood coagulation capacity of a patient cannot be reduced, and the risk that a wound cannot be healed can be effectively reduced.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

This utility model belongs to the field of medical device technology, specifically relating to a double-lumen central venous catheter with anti-wall adhesion and anticoagulation functions, including an extension tube, a double-lumen catheter, and a connector; the extension tube is connected to the double-lumen catheter through the connector; the double-lumen catheter is divided into two inlet lumens by a diaphragm, and the two inlet lumens are connected to two corresponding extension tubes; a side hole and a main hole are provided at the end of the double-lumen catheter, and the end of the double-lumen catheter has a C-shaped segment, with the side hole located on the concave side of the C-shaped segment, and the main hole located at the end of the double-lumen catheter. The C-shaped segment in this design reduces the occurrence of the side hole adhering to the blood vessel wall, reducing the probability of local coagulation and thrombosis when used for pediatric hemodialysis blood drainage; the biomimetic sharkskin microgrooves etched on the outside of the double-lumen catheter reduce resistance to blood flow and thrombus formation; the biomimetic sharkskin microgrooves can be filled with covalently grafted sulfonated heparin-hydrogel, continuously releasing anticoagulant factors, further reducing the formation of wall-attached thrombi.

The application provides an intelligent atrial fibrillation anticoagulation bleeding risk assessment system and method. The system comprises a patient data acquisition module for acquiring gene mutation site data, drug exposure data, anticoagulation activity data, clinical feature data and follow-up bleeding event data; a data checking and fusing module for quality checking, time alignment and feature fusing of the data to generate anticoagulation bleeding correlation features; a site correlation modeling module for constructing a conduction correlation model between the gene mutation site and the drug exposure offset, the anticoagulation activity offset and the follow-up bleeding event based on the anticoagulation bleeding correlation features; and a risk assessment module for determining the anticoagulation bleeding risk representation of a target atrial fibrillation patient according to the conduction correlation model, decomposing the anticoagulation bleeding risk representation into risk sources, and generating an intelligent atrial fibrillation anticoagulation bleeding risk assessment result containing risk level and risk source information. The application can improve the assessment accuracy, enhance individual identification and improve the result interpretability.

The invention belongs to the technical field of biology, and relates to an anticoagulant fusion protein HSA-Qinghaenin (c), a coding gene and application thereof, in particular to preparation of the anticoagulant fusion protein and application of the anticoagulant fusion protein in the fields of prevention of in-vivo thrombus formation and preparation of anticoagulant coating biological materials. Compared with an existing anticoagulant coating, the material surface anticoagulant coating based on the anticoagulant fusion protein HSA-Qinghaenin (c), provided by the invention, shows remarkable advantages. Through self-polymerization of polydopamine, the adhesiveness of the coating and a substrate material is greatly improved, and the stability and durability of the coating are ensured. HSA in the anticoagulant fusion protein HSA-Qinghaenin (c) can inhibit the adsorption of plasma proteins and platelets, the Qinghaenin (c) takes FXII in an endogenous blood coagulation pathway as a target spot, the activation of a blood coagulation factor is inhibited, meanwhile, the risk of inducing bleeding is avoided, and the HSA-Qinghaenin (c) can play a role of'one stone and two birds' in the aspect of anticoagulation of a biological material.

The application discloses a kind of dabigatran bleeding risk prediction methods based on machine learning, it is related to computer-aided drug risk management technical field, the method is by obtaining patient baseline and follow-up data, multiple imputation method is handled missing value;With HAS-BLED score as the basis, candidate variables are screened from potential risk factors using LassoCV algorithm, and anemia, insulin use and antifungal agent use are determined as new prediction variables through clinical correlation analysis to construct a set of prediction variables;Finally, a random forest or gradient boosting algorithm is used to train the model to output the bleeding risk assessment results of the individual to be tested.The application combines machine learning algorithm, improves the prediction accuracy of dabigatran bleeding risk in Chinese non-valvular atrial fibrillation patients, solves the problem of insufficient prediction accuracy of traditional HAS-BLED score, and provides a more reliable basis for clinical individualized anticoagulant therapy decision.

The invention discloses a blood routine microsphere, a preparation method thereof and application of the blood routine microsphere in a vacuum blood collection tube, and belongs to the technical field of medical instruments. The blood routine microsphere is composed of ethylenediamine tetraacetic acid salt and an excipient, all the components are dissolved in deionized water to form a solution, the solution is rapidly frozen in liquid nitrogen through a bead dropping machine to form a microsphere precursor, and then the freeze-dried microsphere with the diameter of 2.0-6.0 mm is prepared through a vacuum freeze-drying process. The microspheres have the characteristics of uniform particle size, rapid dissolution and stable anticoagulation effect. The microspheres are applied to a vacuum blood collection tube. According to the invention, the production process of the traditional vacuum blood collection tube is simplified, the defects that the liquid anticoagulant is not uniformly sprayed and blood coagulation is easily caused are overcome, the product quality and the production efficiency are improved, and the production cost is reduced.

The invention relates to the field of medical health and intelligent optimization, and discloses a dialysis anticoagulation risk intelligent early warning method and system fused with multi-modal physiological signals, and the method comprises the steps: S1, synchronously collecting the multi-modal data of a patient in the dialysis process, and standardizing the multi-modal data into a unified time sequence matrix; s2, inputting the unified time sequence matrix into an anticoagulation risk prediction model, performing first-class feature extraction on continuous monitoring signals, performing second-class feature extraction on discrete detection signals, and extracting embedding features of patient individualization and treatment scene data; performing cross-modal fusion on the three types of extracted features to generate a fusion feature vector, and outputting a thrombus risk probability and a bleeding risk probability in a future preset time period; s3, when the risk probability exceeds the corresponding early warning threshold value, performing search optimization on the administration parameter of the current anticoagulant, and generating a dose adjustment instruction; and S4, executing the adjustment instruction, predicting the anti-coagulation risk again, and evaluating the regulation and control effect. Therefore, the safety and effectiveness of the hemodialysis process are remarkably improved.

The invention discloses a blood sampler, and relates to the technical field of blood sampling. Comprising a blood collection piece, a flow guide piece is installed in the blood collection piece, and the flow guide piece is used for guiding blood to the bottom of the blood collection piece; the blood collection piece is sleeved with a lifting adjusting piece; a lifting isolation piece is mounted in the blood collection piece; the lifting isolation piece magnetically attracts the lifting adjusting piece; a puncture sampling piece is mounted on the blood collection piece; an anticoagulant is conveniently drained to the inner side of the drainage tube by utilizing the lifting isolation piece, and the flow guide piece can be used for draining blood, so that the blood can be conveniently and directly discharged from an anticoagulant solvent at the bottom of the blood collection tube during collection, and the anticoagulant effect is ensured; the problems that according to an existing blood sampler, direct anticoagulation drainage to a solvent is not convenient, clear liquid is not convenient to isolate, protect and separate, and butt joint is tedious through manual single-hand operation are solved.

The invention discloses a portable hemodialysis instrument capable of preventing a loop from being blocked, and relates to the technical field of hemodialysis instruments. The blood pumping device comprises a shell, a reciprocating driving mechanism is arranged in the shell, a piston film is fixedly installed in a loop cavity in the shell, the reciprocating driving mechanism drives the piston film to reciprocate for blood pumping operation, and a sealing cover is fixedly installed at the end of the shell. According to the device, blood enters extracorporeal circulation through the connecting end, the flow monitoring mechanism monitors the blood flow of the blood inlet end and the blood return end in real time, when it is detected that the flow of the blood inlet end is obviously lower than the flow of the blood return end, it is indicated that thrombus is possibly formed or blockage is likely to happen in a loop, and at the moment, the anti-coagulation and anti-blocking mechanism is immediately started; the blood inlet pipeline is accurately filled with anticoagulant, initial thrombus is actively dissolved, and blockage expansion is prevented, so that manual shutdown cleaning in the background technology is avoided, dialysis continuity and safety are guaranteed, and one-way flowing of blood is guaranteed through the one-way valves on the two connecting ends.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by anticoagulants such as an Xa factor inhibitor, and has the characteristics of broad spectrum and high efficiency.

The utility model relates to the field of medical auxiliary instrument, concretely relates to a portable blood sample anticoagulation mixing device, including mixing support base, detachable connection is established the sealed protective cover of mixing support base upper end, the upper end fixed connection of sealed protective cover has the carrying handle, still including mixing mechanism, the utility model discloses the whole device adopts compact structure design, need not power, solve the poor portability of existing device, the problem of dependence on commercial power, the device realizes the bidirectional swing of blood collection tube through pressing drive swing, solve the problem that uneven mixing caused by manual swing in the prior art, the problem that the blood cell is broken caused by excessive force, the inner wall that test tube is placed is equipped with rubber antiskid pad and multiple groups of rubber protruding, solve the problem that the existing device fixed inner diameter, poor adaptability.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by anticoagulants such as a thrombin direct inhibitor, and has the characteristics of broad spectrum and high efficiency.

The application discloses a liquid inlet device of a thrombolytic catheter, which comprises a catheter main body, a sealed box and a propelling assembly. The outer side of the catheter main body is sleeved with an outer pipe, the inner side surface of the outer pipe is provided with a flow guide groove, the inner bottom wall of the flow guide groove is provided with a plurality of flow guide holes, the outer pipe end part located on the outer side of a human body is fixedly connected with a flow guide ring which is internally hollow, each flow guide groove is communicated with the inner part of the flow guide ring, the sealed box is placed with a bag body which internally contains an anticoagulant liquid, the sealed box is communicated with the inner part of the flow guide ring through a branch pipe, and the propelling assembly is communicated with the inner part of the sealed box through a connecting pipe. The sealed box is inflated through the propelling assembly, the air pressure is enhanced to extrude the bag body when the gas enters the sealed box, the anticoagulant liquid in the bag body is slowly and continuously flowed into a plurality of flow guide grooves through the branch pipe, and then is flowed out of a blood vessel cavity, so that the formation of a cavity intramural thrombus is reduced, and then the whole blood vessel cavity continuously has a trace amount of anticoagulant drug, which can effectively dissolve the thrombus in the blood vessel cavity and on the outer wall of the thrombolytic catheter.

A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.

The invention belongs to the field of medical care informatics, and provides an extracorporeal circulation-oriented anticoagulation regulation and control intelligent management system and method, and the method comprises the steps: constructing a feature vector for representing the current anticoagulation demand of a patient; calculating an expected cumulative reward for each policy agent by exploring a long-term effect between different heparin infusion adjustment policies and the individual state of the patient; dynamically modeling a short-term relationship among different heparin infusion adjustment strategies, a patient real-time blood coagulation activation time deviation target value and a heparin concentration safety range through a probability density function, and generating a specific heparin infusion rate adjustment amount; receiving the heparin infusion rate adjustment amount, and updating the heparin infusion rate in real time according to the heparin infusion rate adjustment amount; the real-time coagulation activation time deviation target value of the patient and the current heparin concentration are fed back to the global optimization module and the local optimization module, and strategy parameters are continuously corrected.

The utility model relates to the field of blood collection tubes, in particular to an anti-falling type anti-coagulation vacuum blood collection tube which comprises a blood collection tube body, a fixing body, a connecting body, a blood guide tube, a sealing plug, a sealing film, a sealing gasket, an anti-pressing cylinder and a needle head, the fixing body is installed on the upper side of the blood collection tube body, and the sealing gasket is installed between the blood collection tube body and the fixing body. The connecting body is installed on the upper side of the fixing body, the anti-pressing barrel is installed in the middle of the upper side of the connecting body, the blood guiding pipe is installed in the anti-pressing barrel, the blood guiding pipe at the connecting position can be prevented from being pressed through the anti-pressing effect of the anti-pressing barrel, and the risk that blood guiding is blocked and unsmooth due to pressing is avoided; a sealing film is arranged at the joint of the bottom of the inner side of the anti-pressing cylinder and the blood guide tube; a sealing plug is arranged at the right end of the anti-pressing cylinder.

The application discloses a blood sampling device for blood culture, which comprises a flexible catheter, a blood sampling needle assembly and a bottle body puncture assembly arranged at two ends of the flexible catheter, and a volume-adjustable quantitative assembly arranged in the middle section of the flexible catheter; the quantitative assembly comprises a flexible inner capsule in communication with the inner cavity of the catheter, a rigid outer cavity body wrapped outside the inner capsule, and a volume adjusting mechanism for adjusting and limiting the effective expansion volume of the inner capsule; the catheter is provided with a first switch valve and a second switch valve, and the inner wall of the catheter and / or the inner wall of the inner capsule is provided with an anticoagulant coating. The application realizes flexible adjustment and accurate control of the blood sampling volume by a mechanical limiting mode, can meet the blood sampling requirements of different patient groups by one set of device, and unifies the production standard without producing multiple specifications. The blood sampling process of the device is completed in a closed pipeline, and the device is matched with an integrated multi-bottle puncture adapter, so that the quantitative blood sample can be continuously and aseptically distributed to multiple blood culture bottles under one-time venous puncture, and the device is convenient to operate and accurate in quantification.

The invention provides a PH-viscosity dual-response fluorescent probe, a preparation method and application, belongs to the technical field of fluorescent probes, and is technically characterized in that the structural formula of a probe molecule is shown in the specification. By optimizing a fluorescent skeleton and hydrophilic modification and calibrating pH / viscosity response mapping, the application can be used for rapidly screening a blood coagulation function, evaluating an anticoagulation treatment effect or researching and developing a portable thrombus detection device.

The invention provides an anticoagulant hollow fiber membrane for blood purification and a preparation method thereof, and relates to the technical field of medical polymer membranes, and the preparation method comprises the following steps: respectively introducing a spinning solution and an internal solidification solution into a coaxial spinning nozzle for hollow fiber spinning, so that the spinning solution is firstly in contact with the internal solidification solution on a lumen side, an initial phase separation interface is formed on the lumen side, and the initial phase separation interface is formed on the lumen side; according to the preparation method, a hydrophilic polymer component and a surface anticoagulation modification component are introduced into a polyether sulfone membrane matrix, and the solvent exchange rate between an internal coagulation liquid and a spinning liquid is controlled in the spinning phase inversion process, so that a sulfobetaine polymer is directionally migrated to a lumen side interface and is enriched on a blood contact inner surface; on the premise of ensuring the structural strength of the membrane body and the stability of the pore structure, a high-density anticoagulation functional layer is constructed on a blood contact interface, so that the separation of structural support and interface functions is realized, the blood compatibility is improved, and the blood coagulation risk is reduced.

The invention relates to a pre-charging and exhausting system for blood purification and a pre-charging and exhausting method, and belongs to the technical field of blood purification. The pre-charging and exhausting system for blood purification comprises a first clamp, a blood pump, a blood purifier and a second clamp which are sequentially arranged in the blood flowing direction and connected through a circulating pipeline, and further comprises an infusion apparatus, a pulse clamp, a vacuum pump and a high-frequency vibrator, and the infusion apparatus is used for conveying pre-charging liquid and is connected with the circulating pipeline between the first clamp and the blood pump through an infusion tube; the pulse clamp is arranged on the infusion tube and is configured to be periodically opened and closed so as to produce pressure pulses in the circulating pipeline; the vacuum pump is communicated with an inner cavity of the blood purifier; and the high-frequency vibrator is connected with the blood purifier. The invention aims to improve the discharge effect and discharge efficiency of gas in the blood purifier in the pre-inflation and exhaust link before the formal start of blood purification treatment, shorten the preparation time of the blood purification treatment, improve the anticoagulation effect of the blood purification treatment, and reduce the adverse effect caused by blood coagulation of the blood purifier.

The invention relates to the technical field of medical instruments, in particular to an anti-blocking self-elution flow divider for treating hydrocephalus, which comprises a liquid storage vessel, the outer wall of the liquid storage vessel is provided with a liquid inlet hole, the inner wall of the liquid storage vessel is rotatably connected with a micro turbine, and the outer wall of a rotating shaft of the micro turbine is fixedly connected with a micro fan blade. Heavy impurities are separated through centrifugal force generated by flowing of cerebrospinal fluid through the liquid storage vessel and the tangentially-formed liquid inlet holes, the hidden danger of blockage is reduced fundamentally, the coating of the drainage tube can also actively degrade attached blockages such as protein and biological membrane matrixes, and through the drainage tube, the functional coating of the drainage tube is utilized, so that the drainage effect is improved. Depending on the slow release characteristic of the biodegradable polymer matrix and the long-term effect of the catalyst, the degradation function can last for a long time, the expected service life of the shunt tube is matched, meanwhile, the coating integrates the antibacterial function and the anticoagulation function, shunt failure caused by infection and thrombus is reduced, and the service life is further prolonged.

The invention belongs to the technical field of anticoagulant drugs, and particularly relates to lumbricus protein with anticoagulant activity as well as a preparation method and application of the lumbricus protein. The lumbricus protein provided by the invention contains at least one of a c71616 protein with an amino acid sequence as shown in SEQ ID No. 1, a c128686 protein with an amino acid sequence as shown in SEQ ID No. 2, a c58213 protein with an amino acid sequence as shown in SEQ ID No. 3 and a c118923 protein with an amino acid sequence as shown in SEQ ID No. 4. The protein can effectively inhibit thrombin activity and interfere formation of fibrin so as to act on a key link of a blood coagulation process. The protein can be obtained through recombinant expression and purification, and has high expression efficiency and stability, so that the protein can be used as an active component to be applied to development of anticoagulant drugs, surface anticoagulant coatings and other products.

The invention relates to the technical field of blood sample collectors, and discloses a disposable human arterial blood sample collector, which comprises a sample storage device of a cylindrical hollow structure, and the sample storage device is configured to store a collected arterial blood sample; the breathable sealing cap is connected with one end of the sample storage device, the breathable sealing cap is provided with an expanding central pipe, an annular support frame, a gas filtering membrane and an exhaust groove, and the breathable sealing cap is configured to adjust gas flow in the sample storage device and isolate bacteria; the metal ball assembly is arranged at the bottom of the sample storage device, the metal ball assembly is provided with a metal ball, an anti-blocking bulge and a guide groove, and the metal ball assembly is configured to assist blood anticoagulation. The device effectively ensures smooth collection of arterial blood, effective discharge of gas, anticoagulation of blood samples, and prevention of backflow and blockage.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by antiplatelet drugs and other anticoagulants, and has the characteristics of broad spectrum and high efficiency.